Latest Administration News

ResMed Inc. posted a 10% rise in fiscal 2026 revenue to $5.65 billion, bolstered by the acquisition of Noctrix Health and an agreement to sell its MatrixCare business. The company continues to invest in AI-powered digital health solutions amid ongoing patent litigation and a shifting regulatory landscape.

Global X Metal Securities Australia Limited has refreshed its prospectus for five classes of precious metals securities, maintaining physical bullion backing and ASX AQUA listing, with detailed disclosures on structure, fees, risks, and tax implications.

Bell Financial Group surged to a $21.7 million half-year profit, more than doubling its net profit on stronger markets and the launch of its Bell Potter Private Wealth platform. The company also lifted its interim dividend by 67%, reflecting confidence in its diversified financial services model.

Archer Materials has pinpointed a capillary blood collection method that matches venous samples in haemolysis levels, advancing its potassium Biosensor development towards integrated clinical testing.

Sequoia Financial Group has scrapped its fully franked interim dividend for the half-year ended December 2025, citing ongoing Federal Court proceedings and related legal claims. The Board prioritises capital preservation and risk reduction as the company navigates complex litigation tied to its InterPrac subsidiary.

FINEOS Corporation Holdings PLC reported a robust half with 7.9% total revenue growth, a 32% jump in EBITDA, and a return to net profit driven by subscription sales and operational efficiencies.

NeuroScientific Biopharmaceuticals (ASX:NSB) has locked in a key FDA Pre-IND meeting for late August, advancing its Phase 2 trial plans for StemSmart™ targeting refractory Crohn’s disease in the US and Australia.

Cauldron Energy has begun trading on the US OTCQB market, broadening access to American investors without issuing new shares. This move taps into growing US demand for uranium, positioning Cauldron as a potential supplier from its Yanrey Uranium Project.

Anteris Technologies posted a $51.7 million loss in H1 2026 amid ramped-up R&D and clinical trial activity, supported by a $320 million capital raise and Medicare reimbursement for its DurAVR heart valve trial.

EBR Systems marked a commercial milestone with over 100 WiSE CRT implants and secured purchasing agreements with three major US healthcare networks. The company is progressing toward Medicare coverage and scaling manufacturing, supported by a near-complete A$150 million capital raise.

Adslot Technologies has formalised a Deed of Company Arrangement following voluntary administration, aiming to satisfy non-related creditors while maintaining group control of its digital advertising platform.

AdAlta’s lead CAR-T therapy EW-001 continues to demonstrate encouraging survival and response rates in its mesothelioma study, with all patients alive at the latest follow-up and stronger outcomes at higher doses supporting plans for an Australian Phase 1 trial.